Interleukin-2 production in vitro: a new approach to the study of rabies vaccine immunogenicity as appraised by testing different glycoprotein presentations.
When injected as an immunosome presentation (molecules anchored to preformed liposome), rabies glycoprotein (GP) is capable of protecting animals against rabies either before or after viral infection. The presentation of the GP molecules in the correct form seems to be essential for the induction of antirabies protection. This condition must be taken in account in the making-up of a rabies subunit vaccine. In order to study the relationship between the immune responses induced by the rabies GP and its protective activity, different presentations of the GP were prepared. Purified glycoprotein molecules were associated under different physical forms: liposome-anchored, self-aggregated (rosettes) and associated with the viral lipids (virosomes). These presentations appeared different on electron microscopy. They also exhibited differences in the expression of an immunodominant epitope and in their protective activity. The non-specific immune response, as appraised by interferon production and natural cytotoxicity, was induced at a high level only by the purified viral particles. Specific immune responses (namely virus neutralizing antibody and interleukin-2 production) was induced at high levels only by the viral particle and by the liposome-anchored glycoprotein. A parallelism has previously been established between protection by glycoprotein preparations and interleukin-2 production in primed mice splenocytes. This suggests that the measure of interleukin-2 production in vitro could be used to evaluate the capability of a rabies antigen to induce a T-cell response and to confer protection.
Perrin
P
P
Unité de la Rage, Institut Pasteur, Paris, France.
Joffret
M L
ML
Oth
D
D
Leclerc
C
C
Sureau
P
P
Thibodeau
L
L
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic; D000939:Epitopes; D006023:Glycoproteins / Q000032:analysis / Q000276:immunology*; D006801:Humans; D007372:Interferons / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis*; D007694:Killer Cells, Natural / Q000276:immunology; D008081:Liposomes; D051379:Mice; D008854:Microscopy, Electron; D009500:Neutralization Tests; D011818:Rabies / Q000517:prevention & control; D011819:Rabies Vaccines / Q000032:analysis / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology*
D000914:Antibodies, Viral; D000939:Epitopes; D006023:Glycoproteins; D007376:Interleukin-2; D008081:Liposomes; D011819:Rabies Vaccines; D014764:Viral Proteins; D007372:Interferons